美施康定治疗慢性癌性中重度疼痛的疗效及不良反应  

Clinical Efficacy and Adverse Reactions of Treatment of Moderate to Severe Pain of Chronic Cancerous by Morphine

作　　者：毋彩红[1] 

机构地区：[1]河南煤化焦作煤业(集团)有限责任公司中央医院,河南焦作454150

出　　处：《世界最新医学信息文摘》2012年第9期3-4,7,共3页World Latest Medicine Information Electronic Version

摘　　要：目的探讨美施康定治疗慢性癌性中重度疼痛的疗效和不良反应。方法选择2009年2月．2012年2月期间在我院接受治疗的52例慢性癌性中重度疼痛患者为研究对象，采用美施康定进行治疗，初始剂量为10mg／12h。随疼痛的缓解程度进行剂量调整，治疗2周，观察患者的疼痛缓解情况和不良反应情况。结果美施康定治疗癌性疼痛总有效率为94．23％，其中中度疼痛有效率为100％，重度疼痛有效率为93．33％，不良反应发生率为44．23％，主要不良反应为便秘、恶心呕吐、头晕等。结论美施康定治疗慢性癌性中重度疼痛疗效显著，不良反应相对较少，能显著改善患者的生活质量。值得推广选用。Objective To investigate clinical efficacy and adverse reactions of treatment of moderate to severe pain of chron- ic cancerous by Morphine. Methods 52 patients with moderate to severe pain of chronic cancerous in our hospital from Febru- ary 2009 to February 2012 treated by Morphine.The initial dose was 10mg/12h, dose adjustment with the degree of pain relief, two weeks of treatment, pain relief and adverse events observed in patients. Results The total effective rate was 94.23% , The effective moderate pain was 100%, and the effective rate of severe pain was 93.33% , the adverse reaction rate was 44.23%. Conclusion The clinical efficacy of treatment of moderate to severe chronic cancerous pain is significant, adverse reactions are relatively small , can significantly improve the.quality of life of patients.

关 键 词：美施康定 慢性癌性中重度疼痛 不良反应 

分 类 号：R749.053[医药卫生—神经病学与精神病学]